Hefei-based Origin Quantum has demonstrated its computer’s ability to process medical imaging data ‘exponentially faster’ ...

Researchers say GlycoCaging may offer a route to rescue promising drug candidates that currently show unacceptable systemic ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

Learn how AI in drug discovery is revolutionizing therapeutic development and addressing challenges in cell and gene therapy.

Net Loss: The Company reported a net loss attributable to common stockholders of $29.3 million for the three months ended March 31, 2025, which included $3.2 million of stock-based compensation, ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Research and development expenses for the first quarter of 2025 were $42.9 million versus $20.7 million for the comparable ...

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Massachusetts-based XtalPi will see the firms work on molecular modelling software that can be applied to drug-like small molecules. Charlotte Allerton, Pfizer's head of medicine design ...

Consider routine follow-up, especially after medication has been stopped Gabapentinoids, including gabapentin and pregabalin, are a class of drugs that have anticonvulsant, analgesic, and anxiolytic ...